Drugs / Brentuximab Vedotin
Brentuximab Vedotin
also known as
Adcetris · SGN-35 · Brentuximab · ADCETRIS (brentuximab vedotin) · Brentuximab vedotin brentuximab · Brentuximab vedotina · Brentuximab vedotine · CAC-10 · +5 more
Monoclonal antibody targets TNFRSF8
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed classic Hodgkin lymphoma 1 milestone | |||||
| Filed | US (FDA) | ADCETRIS | classic Hodgkin lymphoma | 2017-11-01 | “Seattle Genetics submitted a supplemental Biologics License Application to the FDA on November 1, 2017.” takeda.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (7) | US (FDA) | ADCETRIS | — | 2015-08-17 – 2025-02-11 | fda.gov ↗ |
| Approved | EU (EMA) | Adcetris | — | 2012-10-25 | europa.eu ↗ |
| Approved | US (FDA) | ADCETRIS | — | 2011-08-19 | fda.gov ↗ |
Trials 171 · started per year
today
US approved 2011
EU approved 2012
1
1
4
3
7
10
23
15
15
13
11
15
10
7
4
10
7
6
6
2
2007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
News releases announcing trial results or a regulatory action · 48
| Date | Issuer | Release |
|---|---|---|
| 2026-03-20 | Bristol-Myers Squibb | Regulatory Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab) bms.com ↗
In the EU, the European Commission (EC) approved Opdivo in combination with brentuximab vedotin for the treatment of children 5 years of age and older, adolescents, and adults up to 30 years of age with relapsed or refractory cHL after one prior line of therapy. |
| 2025-12-01 | Bristol-Myers Squibb | Results Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio bms.com ↗
3-Year Follow-up of the S1826 Study Demonstrated Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma |
| 2025-06-03 | Takeda | Regulatory European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD takeda.com ↗
Takeda ( TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. |
| 2025-02-12 | Pfizer | Regulatory U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma pfizer.com ↗
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS ® (brentuximab vedotin) in combination with lenalidomide and a rituximab product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or chimeric antigen receptor (CAR) T-cell therapy. |
| 2024-12-05 | Pfizer | Results Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS pfizer.com ↗
These findings also underscore the overall survival (OS) advantage over lenalidomide and rituximab plus placebo in patients who have received at least two prior lines of therapy. |
| 2024-06-01 | Takeda | Results Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma takeda.com ↗
The four-year analysis presented by the GHSG showed superior progression-free survival (PFS) and improved tolerability for patients compared to a current standard of care regimen used in Europe in this setting. |
| 2024-06-01 | Pfizer | Results Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma pfizer.com ↗
The four-year analysis presented by the GHSG showed superior progression-free survival (PFS) and improved tolerability for patients compared to a current standard of care regimen used in Europe in this setting. |
| 2024-06-01 | Pfizer | Results Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) pfizer.com ↗
The study showed that the ADCETRIS combination reduced patients’ risk of death by 37% compared to placebo in combination with lenalidomide and rituximab (HR 0.63 [95% CI: 0.445-0.891] p=0.0085). |
| 2024-04-29 | Pfizer | Results Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting pfizer.com ↗
Additionally, results from the Phase 3 ECHELON-3 study of ADCETRIS ® (brentuximab vedotin) in combination with lenalidomide and rituximab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) will be presented for the first time in an oral late-breaking session. |
| 2024-03-12 | Pfizer | Results Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) pfizer.com ↗
Positive outcomes were also observed in key secondary endpoints, including progression free survival (PFS) and overall response rate (ORR). |
| 2023-10-18 | Takeda | Regulatory European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD takeda.com ↗
Takeda ( TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma. |
| 2022-05-26 | Takeda | Results Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma takeda.com ↗
These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination should be considered a standard of care. |
| 2020-11-05 | Takeda | Results Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting takeda.com ↗
Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. |
| 2020-05-15 | Takeda | Regulatory Takeda China announces ADCETRIS ® (brentuximab vedotin) is approved for the treatment of adult patients with CD30-positive Lymphomas takeda.com ↗
Takeda China announced today that ADCETRIS ® (brentuximab vedotin) has been officially approved by China’s National Medical Products Administration (NMPA) for use in adult patients with relapsed or refractory systemic Anaplastic Large Cell Lymphoma (sALCL) or CD30-positive Hodgkin Lymphoma. |
| 2020-05-14 | Takeda | Regulatory European Commission Approves ADCETRIS ® (brentuximab vedotin) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma takeda.com ↗
The European Commission’s decision to approve ADCETRIS for the first-line treatment of patients with sALCL marks a significant milestone for people diagnosed with this devastating condition, |
| 2020-05-13 | Merck Sharp & Dohme LLC | Results Merck’s KEYTRUDA® (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in Head-to-Head Phase 3 Trial merck.com ↗ |
| 2020-03-31 | Takeda | Regulatory Takeda Receives Positive CHMP Opinion for ADCETRIS ® (brentuximab vedotin) in Combination with CHP (Cyclophosphamide, Doxorubicin and Prednisone) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma takeda.com ↗ |
| 2020-03-02 | Merck Sharp & Dohme LLC | Results Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) merck.com ↗
Based on an interim analysis conducted by an independent Data Monitoring Committee (DMC), KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in PFS compared with brentuximab vedotin (BV) in this patient population. |
| 2019-12-09 | Takeda | Results Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS ® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting takeda.com ↗
Four-Year Data Continue to Show Superior Progression-Free Survival of ADCETRIS in Combination with AVD when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma with 31 Percent Reduction in the Risk of Progression or Death |
| 2019-02-11 | Takeda | Regulatory European Commission Approves ADCETRIS ® (brentuximab vedotin) with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma takeda.com ↗
the European Commission (EC) extended the current marketing authorization of ADCETRIS (brentuximab vedotin) to include treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with AVD |
| 2018-12-14 | Takeda | Regulatory Takeda Receives Positive CHMP Opinion for ADCETRIS ® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD takeda.com ↗ |
| 2018-12-04 | Takeda | Results Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS ® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas takeda.com ↗
The data demonstrated that frontline treatment with ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) is effective in extending progression-free survival (PFS) and overall survival (OS) with a safety profile comparable to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), a current standard of care in patients with CD30-expressing peripheral T-cell lymphomas (PTCL). |
| 2018-10-25 | Takeda | Results Takeda to Highlight Data in Hodgkin Lymphoma During the 11 th International Symposium on Hodgkin Lymphoma takeda.com ↗
We look forward to sharing positive data including results from the Phase 3 ECHELON-1 and AETHERA trials, which confirm the long-term benefits of ADCETRIS across treatment lines and support its role as an important targeted therapy for Hodgkin lymphoma. |
| 2018-10-01 | Takeda | Results Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS ® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma takeda.com ↗
The trial demonstrated a statistically significant improvement in progression-free survival (PFS) of ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) versus the control arm, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). |
| 2018-09-21 | Takeda | Regulatory Takeda Obtains Additional Indication and Dosage & Administration for ADCETRIS ® as a Frontline Treatment for CD30-positive Hodgkin Lymphoma in Japan takeda.com ↗ |
| 2018-05-17 | Takeda | Results Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings takeda.com ↗
Data demonstrate greater benefit across these subgroups compared to the intent to treat population regardless of PET2 status based on the primary endpoint of modified progression-free survival. |
| 2018-01-22 | Takeda | Regulatory European Commission Approves ADCETRIS ® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy – Providing an Innovative Treatment Option to Patients takeda.com ↗ |
| 2017-12-11 | Bristol-Myers Squibb | Results Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed or Refractory Hodgkin Lymphoma bms.com ↗
Of 60 response-evaluable patients, 50 patients (83 percent) had an objective response, including 37 patients (62 percent) with a complete response and 13 patients (22 percent) with a partial response. |
| 2017-12-10 | Takeda | Results Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS ® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma takeda.com ↗
Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. |
| 2017-11-14 | Takeda | Regulatory Takeda Receives Positive CHMP Opinion for ADCETRIS ® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma takeda.com ↗ |
| 2017-11-01 | Takeda | Results Takeda to Showcase Data That May Reshape the Future of Blood Cancer Treatments During 59 th American Society of Hematology Annual Meeting takeda.com ↗
Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) as Frontline Therapy Demonstrates Superior Modified Progression-Free Survival versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 ECHELON-1 Study. |
| 2017-10-03 | Takeda | Results Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS ® (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma takeda.com ↗
Estimated Five-Year Overall Survival Rate was 60 Percent and Five-Year Progression-Free Survival Rate was 39 Percent |
| 2017-06-26 | Takeda | Results Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS ® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma takeda.com ↗
Takeda Pharmaceutical Company Limited ( TSE:4502 ) and Seattle Genetics, Inc. ( NASDAQ: SGEN ) today announced that the Phase 3 ECHELON-1 clinical trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (PFS) versus the control arm. |
| 2017-06-15 | Bristol-Myers Squibb | Results Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed Hodgkin Lymphoma at the International Conference on Malignant Lymphoma bms.com ↗
Of 59 response-evaluable patients, 50 patients (85 percent) had an objective response, including 37 patients (63 percent) with a complete response and 13 patients (22 percent) with a partial response. |
| 2017-06-07 | Takeda | Results Takeda and Seattle Genetics Announce Lancet Publication of Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma takeda.com ↗
Today’s publication of the positive results of the ALCANZA trial is another milestone for our brentuximab vedotin clinical program. |
| 2016-12-05 | Bristol-Myers Squibb | Results Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting bms.com ↗
Of 29 response-evaluable patients, 26 patients (90 percent) had an objective response, including 18 patients (62 percent) with a complete metabolic response and eight patients (28 percent) with a partial metabolic response. |
| 2016-12-04 | Takeda | Results Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma takeda.com ↗
Topline data were reported in August 2016 demonstrating the ALCANZA trial met its primary endpoint of achieving a highly statistically significant improvement in the rate of objective response lasting at least four months (ORR4). |
| 2016-11-04 | Takeda | Results Takeda to Present Broad Range of Clinical Data During 58th American Society of Hematology Annual Meeting takeda.com ↗
Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T-Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study |
| 2016-08-01 | Takeda | Results Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma takeda.com ↗
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the Phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL) met its primary endpoint, demonstrating a highly statistically significant improvement in the rate of objective response lasting at least four months (ORR4) . |
| 2016-07-18 | Takeda | Results Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood takeda.com ↗ |
| 2016-07-06 | Takeda | Regulatory Takeda Receives European Commission Approval of ADCETRIS® (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma takeda.com ↗ |
| 2016-05-27 | Takeda | Regulatory Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma takeda.com ↗
the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the current conditional approval of ADCETRIS ® (brentuximab vedotin) and recommended its approval |
| 2016-01-22 | Takeda | Regulatory European Commission Approves Label Variation for ADCETRIS ® (Brentuximab Vedotin) to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma (sALCL) takeda.com ↗
The decision from the EC follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in October 2015. |
| 2015-12-07 | Takeda | Results Takeda Reports Five-Year Overall Survival Data For ADCETRIS® (Brentuximab Vedotin) Demonstrate Durable Remissions in Relapsed/Refractory Hodgkin Lymphoma takeda.com ↗
These results were presented today at the 57th American Society of Hematology (ASH) annual meeting in Orlando, FL. |
| 2014-12-08 | Takeda | Results Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS ® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting takeda.com ↗
The data from the AETHERA trial were featured at the 56th American Society of Hematology (ASH) Annual Meeting press program today and will be presented in an oral session on December 8, 2014. |
| 2014-12-08 | Takeda | Results Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS ® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting takeda.com ↗
At a median follow up of 46.3 months, the estimated four-year survival rate was 64 percent. |
| 2014-09-30 | Takeda | Results Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS ® (Brentuximab Vedotin) for Consolidation in Post-Transplant Hodgkin Lymphoma takeda.com ↗
The AETHERA trial met its primary endpoint with ADCETRIS treatment resulting in a statistically significant improvement in progression-free survival (PFS) versus placebo |
| 2014-01-17 | Takeda | Regulatory Takeda Announces the New Drug Application Approval of ADCETRIS ® (brentuximab vedotin) in Japan for the Treatment of Malignant Lymphoma takeda.com ↗
New Drug Approval of ADCETRIS ® 50mg for intravenous drip infusion for the Treatment for Adult Patients with CD30-Positive Relapsed or Refractory Hodgkin Lymphoma and Relapsed or Refractory Anaplastic Large Cell Lymphoma |
All press releases naming this drug 59 releases
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 183 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | brentuximab vedotin | “Brentuximab Vedotin, 1.8mg/kg/dose, d0、Rituximab, 375 mg/m2, d0、Cyclophosphamide, 750 mg/m2, d1、Doxorubicin, 50 mg/m2, d1、Prednisone, 60mg/m2, d1-5” NCT06925555 ↗176“brentuximab vedotin x 2; doxorubicin x 2; vinblastine x 2; dacarbazine 2x; rituximab x 2” NCT05253495 ↗ “Brentuximab Vedotin Etoposide Cyclophosphamide Doxorubicin Dacarbacine Dexamethasone” NCT06919679 ↗ “CD30 target immunotherapy：Brentuximab Vedotin or CD30-targeting CAR-T Cell Therapy.” NCT07138547 ↗ “Treatment by study drug Brentuximab Vedotin (Adcetris) in combination with CHEP.” NCT05006664 ↗ “1.2 mg/kg brentuximab vedotin i.v. on day 1 of a 21-day cycle” NCT03246750 ↗ |
| Known as | Adcetris | “Brentuximab vedotin, also known as Adcetris, is approved by the United States Food and Drug Administration (FDA) for treatment of certain types of lymphomas, including...” NCT03264131 ↗6“To assess the event free survival (EFS) of a novel regimen incorporating brentuximab vedotin (Bv; Adcetris) in the chemotherapy backbone” NCT02166463 ↗ “Treatment by study drug Brentuximab Vedotin (Adcetris) in combination with CHEP.” NCT05006664 ↗ “Brentuximab Vedotin (BV; Adcetris®) is an antibody-drug conjugate” NCT03187210 ↗ “Brentuximab vedotin (Adcetris)” NCT07013565 ↗ “Trade name: Adcetris” NCT01994850 ↗ |
| Known as | ADCETRIS (brentuximab vedotin) | “ADCETRIS (brentuximab vedotin)” NCT02533570 ↗ |
| Known as | Brentuximab | “This clinical trial uses a drug called Brentuximab Vedotin. The Food and Drug Administration (FDA) has approved Brentuximab Vedotin for sale in the United States for certain...” NCT02588651 ↗1“Brentuximab vedotin is a monoclonal antibody, called brentuximab, linked to a chemotherapy drug called vedotin.” NCT01771107 ↗ |
| Known as | Brentuximab vedotin brentuximab | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742994 ↗ |
| Known as | Brentuximab vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742994 ↗ |
| Known as | Brentuximab vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742994 ↗ |
| Known as | CAC-10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742994 ↗ |
| Known as | Cac10-1006(4) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742994 ↗ |
| Known as | CAC10-VCMMAE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742994 ↗ |
| Known as | Cac10-vcmmae(4) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742994 ↗ |
| Known as | Monoclonal antibody sgn-30 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742994 ↗ |
| Known as | Sgn 30 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742994 ↗ |
| Known as | SGN-35 | “This is a multicenter, open-label study to evaluate single-agent brentuximab vedotin (SGN-35) treatment in patients who previously participated in a brentuximab vedotin study,...” NCT00947856 ↗5“In this study, instead of beginning with ICE chemotherapy, the patient will receive a new drug called Brentuximab vedotin (SGN-35).” NCT01508312 ↗ “Brentuximab vedotin (SGN-35)” NCT01868451 ↗ |
| Action | Deplete | “After the brentuximab vedotin attaches to the CD30 part of the cell, the MMAE enters the cell and kills it.” NCT01671813 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells.” NCT01393717 ↗ |
| Route | Intravenous | “Patients with systemic ALCL and recurrent disease after at least one prior therapy received brentuximab vedotin 1.8 mg/kg intravenously every 3 weeks over 30 minutes as an...” PMID 22614995 ↗ May 2012 |
| Target | TNFRSF8 | “Tumor necrosis factor receptor superfamily member 8 binding agent” CHEMBL1742994 ↗ |